Martínez-Taboada VM

ORCID: 0000-0003-2916-8491 · 5 papers in corpus
2026
Frontiers in immunology ·doi:10.3389/fimmu.2026.1818605

IntroductionTo assess the prevalence and clinical impact of antinuclear antibodies (ANA) and low complement levels on fetal-maternal outcomes in pregnant women within the spectrum of obstetric antiphospholipid syndrome (APS).MethodsA total …

2024
Biomedicines ·doi:10.3390/biomedicines12061174

Inherited thrombophilia (IT) has been implicated as a potential causal factor of adverse pregnancy outcomes (APOs), including recurrent miscarriage with and without the presence of antiphospholipid syndrome (APS). The aim of this study was …

2024
Diagnostics (Basel, Switzerland) ·doi:10.3390/diagnostics14192162

Background/Objectives: ACR/EULAR has recently developed new classification criteria for antiphospholipid syndrome (APS). The present study aims to analyze the impact of these new 2023 ACR/EULAR classification criteria in a cohort of pregnan…

2022
Clinical reviews in allergy & immunology ·doi:10.1007/s12016-021-08915-9

The adjusted Global Antiphospholipid Syndrome (APS) Score (aGAPSS) is a tool proposed to quantify the risk for antiphospholipid antibody (aPL)-related clinical manifestations. However, aGAPSS has been validated mainly for thrombotic events …

2022
Biomedicines ·doi:10.3390/biomedicines10112938

This study aims to compare the demographic characteristics, clinical features, serology, and fetal-maternal outcomes between women with obstetric antiphospholipid syndrome (APS) and those with non-criteria (NC)-APS and seronegative (SN)-APS…